Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, ...
7 years ago
R&D
All in on novel target GSK-3β, Actuate Therapeutics raises $21M+ to bankroll ambitious PhI/II
7 years ago
Financing
Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients
7 years ago
Pharma
AbbVie/Roche's Venclexta wins fourth approval; WuXi, fellow CRO Altasciences ink deal
7 years ago
News Briefing
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
7 years ago
Discovery
After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal
7 years ago
R&D
Pharma
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
7 years ago
R&D
Discovery
Analysts spotlight the winners — and losers — on ASCO preview night
7 years ago
R&D
Pharma
As Daiichi Sankyo-partnered breast cancer drug marches toward finish line, AstraZeneca brings in Canadian scientist ...
7 years ago
People
Ginkgo BioWorks picks up antibiotics effort with Roche where Warp Drive Bio left off
7 years ago
R&D
Can we stop cancer cells from evolving and developing drug resistance? British scientists take a leaf out of the HIV ...
7 years ago
Discovery
IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences
7 years ago
News Briefing
J&J polishes up its new list of late-stage blockbuster candidates — and cancer remains big
7 years ago
R&D
Pharma
ImmunoGen shares tank (again) after the FDA nixes a shot at an OK for its armed antibody in wake of a failed PhIII
7 years ago
R&D
Pharma
Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large
7 years ago
R&D
Vertex wagers $70M on Kymera and its new fascination with protein degradation
7 years ago
R&D
A top exec at struggling Biogen jumps ship for a new job
7 years ago
R&D
Pfizer, Merck KGaA clinch needed approval for Bavencio, directly competing against Keytruda in kidney cancer
7 years ago
Pharma
Almost half of all new drug approvals in 2018 relied on one clinical trial
7 years ago
Pharma
FDA+
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
7 years ago
R&D
Daiichi Sankyo 'disappointed' as FDA experts spurn AML drug but vote in favor of rare tumor drug
7 years ago
R&D
Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ ...
7 years ago
News Briefing
Myovant's relugolix clears first uterine fibroids PhIII test, but competition from AbbVie/Neurocrine makes investors ...
7 years ago
R&D
Rejigging Merck KGaA partnership, Eliot Forster gains full control of the alpha in F-star's constellation
7 years ago
R&D
First page
Previous page
949
950
951
952
953
954
955
Next page
Last page